Recombinant Human Nucleoporin NDC1 (TMEM48)

What is the structural and functional role of NDC1 in nuclear pore complex assembly?

NDC1 is a conserved transmembrane nucleoporin integral to NPC architecture. It anchors outer ring scaffold components (e.g., Nup107/160 complex) to stabilize NPCs during assembly . Methodologically, its role has been validated through:

• 3D electron tomography: Revealed a 4.8-fold reduction in NPC density in C. elegans ndc1Δ mutants compared to wild-type .

• Fluorescence recovery after photobleaching (FRAP): Demonstrated NDC1 immobilizes Nup160 in mature NPCs (mobile fraction reduced from 47% to 20% in ndc1 RNAi-depleted cells) .

• Gene knockout models: Co-depletion of ndc1 and nup53 in C. elegans disrupts NE formation, indicating redundant roles in NPC assembly .

Table 1: Key Structural Interactions of NDC1

How does NDC1 expression correlate with cancer prognosis?

Pan-cancer analyses reveal NDC1 overexpression in 28 cancer types, with prognostic significance in 15 . Key methodologies include:

• TCGA/GTEx integration: Log2-normalized RNA-seq data identified elevated NDC1 in HCC (HR = 2.1, p < 0.001) , NSCLC (HR = 1.8, p = 0.003) , and pancreatic cancer (HR = 1.6, p = 0.01) .

• Multivariate Cox regression: NDC1 is an independent prognostic factor for HCC (HR = 1.92, 95% CI: 1.3–2.8) .

• Kaplan-Meier analysis: High NDC1 predicts reduced progression-free survival in 14 cancers (e.g., pancreatic cancer: median survival 12 vs. 21 months, p = 0.006) .

How can researchers resolve contradictions in NDC1’s oncogenic mechanisms across cancer types?

Discrepancies arise from tissue-specific pathways:

• Cell cycle dysregulation: In NSCLC, NDC1 knockdown reduces Cyclin B1, CDK1, and PCNA (70% decrease in G1 arrest) .

• Immune modulation: In HCC, NDC1 correlates with immunosuppressive Treg infiltration (Spearman’s ρ = 0.42, p = 0.002) .

• Apoptosis regulation: Pancreatic cancer models show NDC1 silencing increases caspase-3 activity by 3-fold .

Methodological recommendations:

• Pathway-specific CRISPR screens: Use libraries targeting cell cycle (e.g., Cyclin B1) and immune checkpoints (e.g., PD-L1).

• Single-cell RNA-seq: Resolve tumor microenvironment heterogeneity (e.g., stromal vs. malignant cell NDC1 expression).

• Organoid models: Validate tissue-specific effects using patient-derived HCC vs. pancreatic cancer organoids.

What experimental strategies validate NDC1 as a therapeutic target?

• In vitro functional assays:

  • MTT/EdU proliferation: NDC1 knockdown reduces pancreatic cancer cell viability by 60% (IC50 = 12 µM) .

  • Transwell migration: NSCLC cell migration decreases by 75% post-siRNA treatment .

• In vivo xenografts: NDC1-silenced NSCLC tumors show 50% volume reduction in nude mice .

• Drug sensitivity profiling: NDC1-high pancreatic cancers exhibit resistance to gemcitabine (IC50 increase from 8 nM to 32 nM) .

Table 3: Functional Assays for NDC1 Validation

How does NDC1 influence the tumor immune microenvironment?

NDC1 expression correlates with immune evasion mechanisms:

• TCGA immune deconvolution: Positive association with Tregs (ρ = 0.42) and M2 macrophages (ρ = 0.38) in HCC .

• Immunotherapy response: NDC1-high tumors show reduced PD-1 inhibitor efficacy (ORR = 15% vs. 35% in NDC1-low) .

• Cytokine profiling: IL-10 and TGF-β levels increase 2-fold in NDC1-overexpressing HCC cell supernatants .

Methodological approach:

• Multiplex IHC: Co-stain for NDC1, CD8+ T cells, and PD-L1 in tumor sections.

• CyTOF mass cytometry: Profile immune cell subsets in NDC1-silenced vs. control tumors.

Methodological Guidelines for Future Studies

• Bioinformatics Workflows:

  • GSEA: Prioritize cell cycle (NES = 2.1, p < 0.001) and DNA repair pathways .

  • WGCNA: Identify co-expressed immune checkpoints (e.g., PD-L1, CTLA-4) .

• Translational Models:

  • Use patient-derived xenografts (PDXs) with CRISPR-edited NDC1 alleles.

  • Test NDC1-targeted CAR-T cells in immune-competent murine models.

• Data Reconciliation:

  • Apply meta-analysis frameworks (e.g., random-effects models) to harmonize pan-cancer vs. tissue-specific findings.